Executive Briefing Series
A Dec. 2 article on Avastin in FDL should have said the correct dosage in one arm of the AVADO study was 15 mg/kg. The correct median progression-free survival (PFS) difference for the trial’s 7.5 mg/kg arm was 0.7 months. No new safety signals were observed in AVADO or RIBBON 1 and the safety profile of Avastin was consistent with previous studies including E2100. The FDA withdrew approval of Avastin for metastatic breast cancer Nov. 18.

To View This Article: